Table 2 of Engler, Mol Vis 2009; 15:629-637. Table 2 of Engler, Mol Vis 2009; 15:629-637.
Table 2. Previous studies of human corneal endothelial cell genetic modification.
| Method | Rate of transfection | Reference |
|---|---|---|
| Viral vectors | ||
| adeno-associated virus, HSV | 2%–5% | [12] |
| EIAV | 30% | [5] |
| EIAV, adenovirus, HIV, PFV | 43%–99% | [13] |
| adenovirus | up to 96% | [14] |
| Lipid-/liposome-/peptide-mediated | ||
| Lipofectin | 17%±2% | [18] |
| DMRIE-C | 11%±1% | [18] |
| Effectene | 9%±1% | [18] |
| Fugene | 9%±1% | [18] |
| DAC-30 | 7%±1% | [18] |
| peptides (polyamidoamine) | 2% | [19] |
| Electroporation | ||
| GenePulser (BioRad) | area of clonal proliferation | [20] |
| Easyject Plus system (Eurogentec) | 2.4% | [21] |
| GenePulser (BioRad) | large number of clones | [22] |